In this issue:
Management of colorectal adenocarcinoma metastases
Flexible sigmoidoscopy and CRC incidence
FOLFOXIRI + bevacizumab for mCRC?
Panitumumab vs cetuximab in chemotherapy-refractory mCRC
Primary tumour resection in CRC with unresectable metastases
KRAS mutation matters in FOLFOX-treated stage II/III CRC
FOLFIRI + cetuximab preferred first-line in mCRC?
EGFR inhibitor + chemotherapy benefits WT RAS tumours
Combination therapy with oxaliplatin superior in stage III CRC
Important differences between distal and proximal tumours
Please login below to download this issue (PDF)